The U.S. Food and Drug Administration (FDA) has asked Endo Pharmaceuticals to remove its opioid pain medication, reformulated Opana ER, from the market because of the public health consequences of abuse. This is the first time the FDA has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse. The reformulated product showed a greater tendency for injection abuse, which has been associated with HIV, hepatitis C, and a serious blood disorder. The FDA intends to take steps to formally require removal by withdrawing approval of the medication, if the company does not voluntarily remove it from the market. To read more, go to